**Emergent BioSolutions Inc. Reports Fiscal Year 2025 Results**

Emergent BioSolutions Inc., a global life sciences company focused on preparedness and response solutions for public health threats, reported its fiscal year 2025 financial results. The company's total revenue for the year was $742.9 million, a decrease of 29% compared to the $1.04 billion reported in 2024. This decline was primarily attributed to lower commercial product sales, which decreased by $172.8 million, and a decrease in MCM product sales by $53.1 million. The company reported a net income of $52.6 million, a significant improvement compared to the net loss of $190.6 million in the previous fiscal year.

The company's commercial product segment, which includes NARCAN® Nasal Spray and KLOXXADO® Nasal Spray, generated $226.1 million in revenue, a 43% decrease from the $398.9 million reported in 2024. This decline was primarily driven by increased competition from generics impacting price and unit sales of OTC NARCAN® and lower Canadian sales of branded NARCAN®, partially offset by an increase in KLOXXADO® sales. The MCM product segment, consisting of Anthrax, Smallpox, and other medical countermeasures, reported $456.7 million in revenue, a 10% decrease compared to the $509.8 million in 2024. This decrease was primarily due to lower ACAM2000® sales volumes to both U.S. and non-U.S. customers, partially offset by increases in sales of TEMBEXA® and CNJ-016® (VIGIV).

Operationally, Emergent BioSolutions continued to streamline its manufacturing network and strengthen execution capabilities. In March 2025, the company completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International for approximately $36.5 million. The company also expanded its naloxone portfolio through the acquisition of exclusive commercial rights in the U.S. and Canada to KLOXXADO® (naloxone HCl) Nasal Spray 8 mg from Hikma. The company also secured multiple contract actions during 2025 that support near- and mid-term deliveries, including contract actions for ACAM2000® totaling $56 million, CYFENDUS® totaling $30 million, CNJ-016® (VIGIV) totaling $51.9 million, BAT® totaling $62.4 million, and TEMBEXA® totaling $17 million.

Looking ahead to 2026, Emergent BioSolutions plans to continue executing its multi-year plan with a focus on disciplined execution, improved operating performance, and long-term sustainable growth. Key priorities include reinforcing patient safety, quality, and compliance, leveraging government and stakeholder relationships, maintaining disciplined capital allocation, enabling growth across business lines, advancing strategic partnerships, and expanding global engagement. The company's Board of Directors reauthorized the 2025 Share Repurchase Program for the repurchase of up to $50.0 million through March 31, 2027, demonstrating a continued focus on capital allocation and financial flexibility.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a global life sciences company specializing in developing and manufacturing medical countermeasures, vaccines, therapeutics, and diagnostics for public health threats like bioweapons, infectious diseases, and emergencies. Its core segments include government-focused biodefense products, commercial vaccines like NARCAN, and bioservices supporting drug development. The company leverages government contracts, proprietary technologies, and strategic partnerships to deliver lifesaving solutions worldwide.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.